infliximab chimeric monoclonal antibody sold brand name remicade among others medication used treat number autoimmune diseases includes crohns disease ulcerative colitis rheumatoid arthritis ankylosing spondylitis psoriasis psoriatic arthritis behçets given slow injection vein typically six eightweek common side effects include infections acute infusion reactions abdominal infliximab chimeric monoclonal antibody biologic seems work binding neutralizing tnfα preventing interacting receptors tnfα chemical messenger cytokine key part autoimmune reaction infliximab originally developed mice mouse antibody humans immune reactions mouse proteins mouse common domains replaced similar human antibody domains monoclonal antibodies identical structures affinities target combination mouse human antibody amino acid sequences called chimeric monoclonal citation needed infliximab approved medical use united states european union august infliximab biosimilars approved eu japan united states world health organizations list essential three phenotypes categories disease present crohns disease stricturing disease causes narrowing bowel penetrating disease causes fistulae abnormal connections bowel inflammatory disease primarily causes infliximab first used closure fistulae crohns disease phase ii clinical trial researchers showed infliximab effective closing fistulae skin bowel large phase iii clinical trial called accent trial showed infliximab additionally beneficial maintaining closure fistulae almost twothirds patients treated three initial doses infliximab fistula response weeks patients maintaining closure fistulae year compared received placebo therapy final trial resulted fda approval drug treat fistulizing infliximab used induce maintain remission inflammatory crohns disease accent trial large multicentre trial found patients treated infliximab initial response maintained remission weeks compared received placebo treatment also showed mean maintenance remission weeks compared weeks patients received placebo crohns patients flares disease periods disease quiescence severe flares usually treated steroid medications obtain remission steroids many undesirable side effects gastroenterologists advocating use infliximab first drug try get patients remission called topdown approach infliximab targets tnf thought related cytokines ulcerative colitis thought disease infliximab would limited use however patients ulcerative colitis begun treated infliximab basis two large clinical trials conducted paul rutgeerts william sandborn acute ulcerative colitis treatment trials evaluate utility infliximab ulcerative colitis showed patients treated infliximab year maintained response medication compared patients treated placebo medication two months response patients treated infliximab treated newer drugs etrolizumab similar efficacy infliximab fewer adverse effects treatment ulcerative psoriatic arthritis psa inhibitors tnf infliximab improve signs symptoms several therapies modest efficacy studied nail psoriasis among available agents higher quality data available support efficacy cyclosporine infliximab based studies results suggest infliximab etanercept adalimumab potential reduce signs symptoms moderate severely active axial involvement psa patients inadequate response nsaid level grade antitnf agents infliximab etanercept level grade effective treatment enthesitis traditional agents results suggest infliximab effective treatment dactylitis approved treating ankylosing psoriatic arthritis psoriasis rheumatoid infliximab also prescribed indication treatment behçets infliximab frequently used biological agent treating relapsing half patients saw benefit treatment patients experienced infections cases lead numerous case reports efficacy infliximab various inflammatory skin conditions diseases fda approved infliximab chronic severe plaque psoriasis adults september infliximab used offlabel treating refractory sarcoidosis treatments infliximab tested chronic obstructive pulmonary disease copd evidence benefit possibility infliximab indicated steroid refractory checkpoint inhibitor induced colitis dose infliximab adverse effects lifethreatening common drugs class tnf inhibiting immunosuppressants also includes etanercept enbrel adalimumab humira severe cases leukopenia neutropenia thrombocytopenia pancytopenia fatal reported fda issued warning doctors appearing respective product labeling infliximab instructing screen monitor potential patients fda issued warning doctors increased risk lymphoma cancers associated use infliximab tumor necrosis factor blockers children maintenance therapy drug versus intermittent sporadic therapy lessens likelihood developing antibodies infliximab known reduce efficacy drug combination treatment methotrexate antifolate drug suppresses immune system shown reduce formation antibodies patients rheumatoid combination therapy immunosuppressants shown reduce likelihood antibodies formed crohns use immunosuppressants may necessary diseases infliximab indicated indiscriminant uses immunosuppressants carry risks infliximab studied monotherapy without concomitant immunosuppressants methotrexate azathioprine psoriasis psoriatic arthritis ankylosing use rheumatoid arthritis requires concomitant use methotrexate us food drug administration fda product labeling however concomitant use methotrexate disease states may help reduce bodys immune response infliximab increase duration efficacymedical citation needed infliximab purified recombinant dnaderived chimeric humanmouse igg monoclonal antibody consists mouse heavy light chain variable regions combined human heavy light chain constant serum halflife days detected serum weeks infusion infliximab neutralizes biological activity tnfα binding high affinity soluble free floating blood transmembrane located outer membranes cells similar immune cells forms tnfα inhibits prevents effective binding tnfα receptors infliximab adalimumab another tnf antagonist subclass antitnf antibodies form naturally occurring antibodies capable neutralizing forms extracellular transmembrane receptorbound etanercept third tnf antagonist different subclass receptorconstruct fusion protein modified form neutralize receptorbound additionally antitnf antibodies adalimumab infliximab capability lysing cells involved inflammatory process whereas receptor fusion protein apparently lacks although clinical significance differences absolutely proven etanercept shown perform worse placebo crohns disease differences may account differential actions drugs efficacy side effectsmedical citation needed infliximab high specificity tnfα neutralize tnf beta tnfβ also called lymphotoxin α unrelated cytokine uses different receptors tnfα biological activities attributed tnfα therefore potentially inhibited infliximab include induction proinflammatory cytokines interleukins enhancement leukocyte movement migration blood vessels tissues increasing permeability endothelial layer blood vessels increasing release adhesion molecules infliximab prevents tnfα induced disease transgenic mice special type mice biologically engineered produce human form tnfα used test drugs might expected affect humans experimental mice develop arthritis result production human tnfα administered disease onset infliximab allows damaged joints healmedical citation needed monoclonal antibodies targeting tnfα golimumab adalimumab certolizumab pegol etanercept also binds inhibits action tnfα monoclonal antibody instead fusion tnfreceptor antibody constant importance tnf development rheumatoid arthritis originally demonstrated george kollias colleagues proof principle studies transgenic animal infliximab developed junming le b jan vilček b new york university school medicine collaboration centocor janssen biotech remicade marketed janssen biotech inc formerly centocor biotech inc united states mitsubishi tanabe pharma japan xian janssen china scheringplough part merck co june two biosimilar versions inflectra remsima submitted approval europe hospira celltrion healthcare positive opinion european medicines agencys ema committee medicinal products human use chmp sale european union celltrion obtained marketing authorization approval maa eu countries eea european economic area countries september inflectra approved use european union september remsima approved use european union october japan celltrion received marketing authorization remsima japans ministry health labour welfare mhlw july needed india epirus biopharmaceuticals obtained approval produce biosimilar infliximab brand name infimab trail name us food drug administration fda approved celltrionhospirapfizers inflectra infliximabdyyb april although us brand name inflectra marketed european union fda approved samsung bioepis co ltds renflexis infliximababda april biogen released another biosimilar flixabi approved germany uk flixabi approved use european union may december ixifi infliximabqbtx approved united zessly approved use european union may december avsola infliximabaxxq approved united avsola approved medical use canada march december ixifi approved medical use united states infliximab expensive medication costing mg dose covered almost every us medical insurance plan though caps many plans make possible covered subset treatments course yearcitation needed infliximab supplied sterile white lyophilized freezedried must reconstituted administered health care professional usually hospital office reason usually covered major medical insurance rather prescription drug coverage loading regimen approved indications occurs weeks uk infliximab available nhs crohns disease treatment provided three criteria patients severe active crohns disease cdai score responded immunomodulating drugs corticosteroids surgery inappropriate since february also approved treatment ulcerative colitis treatments australia infliximab available pbs crohns disease treatment provided patient responded conventional treatment severe case infliximab available republic ireland hses medical card drug payment schemecitation needed johnson johnson reported annual report remicade infliximab accounted approximately companys total revenues fiscal immune activation dostarlimab ibalizumab httpsenwikipediaorgwikiinfliximab